What is the age limit for growth hormone injections?

Growth hormone (GH) injections are a cornerstone treatment for children with growth hormone deficiency and certain growth disorders. But when it comes to starting and stopping GH therapy, age is a crucial factor that can significantly affect outcomes.

When Age Matters in Growth Hormone Therapy

Growth hormone injections are primarily prescribed for children whose bodies do not produce enough GH, leading to slow growth or short stature. The timing of when therapy begins—and when it ends—plays a major role in how much benefit a child receives from treatment.

There is no definitive upper age limit for receiving growth hormone injections, as the therapeutic use of this treatment is determined by the underlying medical condition and the patient's specific needs rather than age alone. However, the reasons for prescribing growth hormone and the typical age ranges for treatment differ significantly between children, adolescents, and adults.

What Is the Age Limit for Starting Growth Hormone Therapy?

GH therapy can technically be started at any age, including infancy, if a deficiency is diagnosed. Treatment most commonly begins between ages 2 and 3, especially for children who have not shown adequate "catch-up" growth after being born small for gestational age.

The upper age limit for starting GH therapy is generally determined by the status of the growth plates (epiphyses) in the bones. Once these plates close—typically around age 14 in girls and 16 in boys—further height increase is not possible.

Commonly-used GH drugs include:

• Somatropin (brands: Genotropin, Humatrope, Norditropin)
• Somatrogon (brand: Ngenla), approved for children ages 3 to 17

Can Adults Receive Growth Hormone Injections?

Yes, adults with confirmed adult growth hormone deficiency (AGHD) can receive GH therapy, but only after specialized testing. In adults with HIV, GH is often used to treat conditions like HIV-associated wasting (cachexia). Approved drugs for adults include somatropin products (such as Genotropin, Serostim, and Humatrope). GH injections are not approved for anti-aging, bodybuilding, or athletic enhancement.

Why Is Early Initiation of GH Therapy Recommended?

Starting GH therapy early—ideally before puberty—leads to the best height outcomes. Early initiation allows for a longer treatment window before the growth plates fuse, maximizing potential growth. Studies show that girls who start before age 8 and boys before age 9 see the greatest height gains. In one study, researchers analyzed data from over 3,000 children in Europe and the United States, dividing them into groups based on the age they started treatment. The results showed that children who began GH therapy at a younger age (between 2 and 4 years old) had a significantly greater improvement in their height after eight years compared to those who started later.

What Happens If GH Therapy Starts Late?

If GH therapy begins after the onset of puberty or after growth plates have closed, the potential for additional height is greatly reduced. However, late initiation may still offer benefits such as improved bone density, increased muscle mass, and better quality of life, especially for adults with AGHD.

What Do Guidelines Say About Age and GH Treatment?

Clinical guidelines from leading medical organizations, including the Pediatric Endocrine Society, the Endocrine Society, and the American Association of Clinical Endocrinologists (AACE), emphasize that the timing of growth hormone (GH) therapy is a critical factor in achieving optimal outcomes. The recommended age for initiating treatment varies depending on the underlying medical condition. The general consensus across all indications is that earlier diagnosis and treatment lead to better results. Drug labels and clinical guidelines always specify that growth hormone therapy should be discontinued when growth plates have fused, as further height increase is no longer possible.

• NICE (UK): Recommends somatrogon (Ngenla) and somapacitan (Sogroya) for children aged 3–17 with GH deficiency.
• FDA (US): Approves somatropin for use in children as young as 1 who have growth failure due to inadequate GH levels. Age is not specified for other conditions that cause growth failure.
• APEG (Australia): Recommends GH therapy before bone age reaches 13.5 years in girls and 15.5 years in boys.

In adults with GHD, which can be either a continuation of a childhood issue or have an adult-onset, the decision to start GH therapy is based on the clinical picture and the underlying cause. The AACE provides age-stratified dosing recommendations for initiating treatment in adults to minimize side effects, with lower starting doses for older individuals.

Is Growth Hormone Safe for Children of All Ages?

When prescribed and monitored by a pediatric endocrinologist, GH therapy is generally safe for children. Common side effects include joint pain, fluid retention, and injection site reactions. Regular monitoring is essential to adjust dosing and watch for rare but serious side effects. Parents are often trained to give injections at home, which may be daily or weekly depending on the medication.

How Long Does GH Therapy Typically Last?

The duration of growth hormone (GH) therapy is not a one-size-fits-all answer, as it largely depends on the patient's age, the underlying medical condition being treated, and the individual's response to the therapy (e.g., growth velocity, bone x-rays). For children, GH therapy is typically a long-term treatment that lasts for several years. The primary goal is to help them reach a normal adult height. Therapy typically stops after growth plate fusion, unless transitioned to adult dosing for AGHD.

For adults with growth hormone deficiency, either carried over from childhood or with adult-onset GHD (often due to pituitary tumors, surgery, or radiation), GH therapy is often a long-term, and potentially lifelong, commitment. The decision to continue GH therapy in adults is based on the ongoing clinical benefits.

Summary

Growth hormone injections are most effective for increasing height when started early in childhood, before puberty and when the growth plates close. It is typically started in children around 2-3 years old, but some treatments are approved for children 1 year and older. Common treatments include somatropin (Genotropin, Norditropin) and Somatrogon (Ngenla). While adults can receive GH for deficiency, the primary age limit for height gain is dictated by bone maturity, not just chronological age. Always consult a pediatric endocrinologist to determine the right timing and duration of therapy for your child.

See also:

Medical Disclaimer